Articles On Immuron

Title	Source	Codes	Date
Recent Updates On 4 Healthcare Stocks- 1AD, IMC, NEU & SCU Healthcare Healthcare sector comprises of the companies that offer medical services, producing medical equipment or medicines. These companies also give medical insurance to the patients. In Australia, the funding of healthcare is taken ca...	Kalkine Media	IMC	6 years ago
Immuron Share Price Climbs 26% with North American Revenue Surge Aussie biopharmaceutical company Immuron Limited [ASX:IMC] is thriving in the early hours of today’s trading. Within the first hour after market open, Immuron shares were up a whopping 26%, to sit at 14.5 cents a share The post Immuron Shar...	MoneyMorning	IMC	6 years ago
Immuron’s Travelan anti-diarrhea product drives record revenue in North America Immuron (ASX: IMC) has revealed its full year 2019 revenue in North America had grown more than 50% to reach $1.16 million – driven by its Travelan gastrointestinal and digestive prophylactic health supplement to prevent traveller’s diarrhe...	SmallCaps	IMC	6 years ago
Trading Places: After three years of suspension, this tin company raised $20 million In this week’s recap of substantial holders, a Dubai executive bought into Prospect Resources (ASX: PSC), Salt Funds Management sold $8.3 million of Monash IVF (ASX: MVF) and a tin company raised $20 million to save itself from the ‘three-y...	Stockhead	IMC	6 years ago
Top 10 at 10: These ASX stocks are in the lead today Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...	Stockhead	IMC	6 years ago
Immuron’s shares rise on the back of Travelan® results Australian biopharmaceutical group, Immuron Ltd (ASX:IMC; NASDQ:IMRN), has provided an extremely promising update on the company’s cooperative research and development agreements with the US Department of Defence, no doubt contributing to i...	FinFeed	IMC	6 years ago
Immuron reports positive results from Travelan testing, develops anti-dysentery vaccine products Australian biopharmaceutical company Immuron (ASX: IMC) has reported positive results from a study designed to test the efficacy of Travelan anti-dysentery medication on non-human primates. The placebo-controlled Shigellosis challenge study...	SmallCaps	IMC	6 years ago
IMC Ramps up DoD and CSIRO Partnerships in Quest to Supply Troops Immuron Limited (ASX:IMC \| NASDAQ:IMRN) has provided a steady stream of positive news across its microbiome immunotherapy platform — which includes assets that are preclinical, at clinical stage, and the already on-the-market Travelan® prod...	NextBiotech	IMC	7 years ago
IMC Reports Rising Revenues & Eyes Colitis Market Immuron Limited (ASX:IMC \| NASDAQ:IMRN) is focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.	NextBiotech	IMC	7 years ago

Articles On Immuron (ASX:IMC)